Increases calcium current amplitude through Cav1.2/Cav1.3 channels in rat pancreatic beta-cells, which is a prerequisite for eliciting insulin secretion. Stimulates insulin secretion in NIT-1 insulinoma cell lines. In vivo, significantly decreases mice blood glucose levels as of 45 minutes after treatement, similarly to insulin treatment. Has a potential therapeutic use in endocrinal pathologies such as early stages of type 2 diabetes where the pancreas's capability to produce insulin is still effective. Expressed by the venom duct. The cysteine framework is XIV (C-C-C-C). Contains 2 disulfide bonds. Belongs to the conotoxin L superfamily.